EMD Serono, a biopharmaceutical unit of Merck KGaA, signed a two-year agreement with the National Multiple Sclerosis Society to speed up research and development of treatments for multiple sclerosis. Under the deal, Merck will invest as much as $19 million in the joint venture and EMD will work with Fast Forward, the society's nonprofit subsidiary.

Related Summaries